Pluripotent
iPSC / ESC
Explore Pluripotent →
The Latest in Cell & Gene Therapy
News and resources for industry professionals.
Cellular Immunotherapy
T cells · NK cells · immune modulation
Explore Cellular Immunotherapy →
Orthobiologics
Bone · cartilage · joints · soft tissue
Explore Orthobiologics →
Neuroregeneration
Brain · spinal cord · peripheral nerves
Explore Neuroregeneration →
Gene Therapy
Delivery · editing · clinical development
Explore Gene Therapy →
Tissue Engineering
Biomaterials · scaffolds · tissue replacement
Explore Tissue Engineering →
All stories
PBS Biotech Teaming Up With Rockwell Automation to Scale Up Cell Therapy Development
The MiniPRO platform runs up to 24 independently controlled bioreactors in parallel, letting developers test processes with automation designed to integrate into larger manufacturing systems.
Boston Children’s Hospital Launches Consortium to Develop Bioengineered Heart Tissues for Children
Researchers plan to test the engineered tissues first in the laboratory and then in large animals, and eventually in humans.
BrightPath Presents Preclinical Data and Phase 1 Trial Design for iPSC-Derived CAR-iNKT Therapy for Multiple Myeloma
The planned trial is designed for patients whose multiple myeloma has returned or resisted treatment after at least three prior lines of therapy.
Century Therapeutics Reports Sustained Glucose Control With iPSC-Derived Islets in Diabetic Mice, IND Soon
In rats, islets delivered through the liver’s portal vein had taken hold one month later, supporting the delivery route planned for clinical testing.
Rivercell Launches With $25M to Build AI Models to Predict Human Cell Responses to Drugs and Genetic Changes
The company is developing a purpose-built laboratory platform to collect large-scale training data on how cells change over time and under treatment.
Vitalant Launches Phoenix Cell-Based Analytics Lab to Support Allogeneic Therapy Developers
Developers will have access to immune profiling and detailed donor assessments, intended to help them evaluate the starting material used to make donor-derived cell therapies.
New Trial – Allogeneic Bone Marrow Mesenchymal Stem Cell Injection for Sarcopenia
The phase 1/2 trial plans to enroll 30 participants to assess CG-BM1’s safety and tolerability, with two doses administered one month apart.
Umbilical Cord Mesenchymal Stem Cell Injections Lower Pain Scores More Than Hyaluronate in 50-Patient Severe Knee Osteoarthritis Trial
Participants received either four stem cell injections two weeks apart or five weekly hyaluronate injections, with outcomes tracked for 12 months.
Stempeutics Nabs US Patent for Osteoarthritis Treatment Combining Bone Marrow Stem Cells and Hyaluronic Acid
The Indian biotech company previously published a Phase 3 RCT comparing its therapy to placebo in 146 KOA patients.
Wolwo Bio Subsidiary Receives Chinese Trial Authorization for Umbilical Cord Mesenchymal Stem Cell Therapy for Sepsis
The company hopes to nab the first approval in the world for this indication.
YiPSCELL Nabs $8M for iPSC-Derived Cartilage Regeneration
YiPSCELL's lead candidate delivers three-dimensional cartilage organoids derived from induced pluripotent stem cells through an injection into the joint cavity.
Inside Cellular Intelligence: The Zuck-Backed AI Company That Acquired Novo’s Parkinson’s Cell Therapy
Cellular Intelligence, backed by the Chan Zuckerberg Initiative, is building an AI model to predict how cells respond to signals over time, supported by a capsule platform that enables exponential experimentation. Here’s our interview with the founder on how it works, plans to advance Novo’s…
I Peace Wins Top 10 Longevity Breakthrough Award for Cell-Free Stem Cell Technology
The experimental product isolates and purifies factors released by lab-grown iPS-derived cells, with foundational studies examining age-related changes in tissues including skin and hair.
New Trial – Phase II Umbilical-Cord Stem Cells for Amyotrophic Lateral Sclerosis
The randomized, double-blind study will enroll about 150 patients to receive intravenous ALT001 at one of two doses or placebo, with functional change assessed at 24 weeks.
Orca Bio Publishes Long-Term Survival Data from TREGZI Blood Stem Cell Therapy
The retrospective analysis compared 76 phase 1b participants with 360 historical registry patients selected using similar age, diagnosis, conditioning and donor-match criteria.
Encellin and Breakthrough T1D Planning Phase 1 of Immune-Protected Cell Therapy for Type 1 Diabetes
The Canadian study will test whether the retrievable implant safely supports donor islets while preventing immune cells from reaching them.
Webinar: Scaling iPSC Therapies Without Scaling Variability
FUJIFILM Cellular Dynamics will present a practical framework for standardizing, automating and scaling iPSC-derived therapy manufacturing.
NurExone and NanoPass Developing Stem Cell Exosomes for Eye and Skin Regeneration
A planned preclinical study will compare MicronJet’s suprachoroidal administration with existing methods, testing whether it can place exosome formulations consistently near the retina and optic nerve.
New Trial – Intranasal Stem Cells for Perinatal Brain Injury and Cerebral Palsy
The UMC Utrecht-sponsored, randomized placebo-controlled study plans to enroll 162 infants with MRI-confirmed hypoxic-ischemic brain injury and assess motor development at 24 months.
RejuvenRx Nabs $700K for Blood Stem Cell Rejuvenation
The C$1 million grant will support development of an oral medicine designed to restore blood-forming stem cells and rebuild the immune system.
FDA Opens Applications for Expedited IND Pilot
Instead of waiting for a complete submission, the program will let selected sponsor–research institution pairs send IND sections for rolling pre-IND review to spot problems earlier.
SMSbiotech Receives FDA Clearance for Inhaled Stem Cell Therapy COPD Trial
The blood-derived, off-the-shelf cells are administered directly to the lungs through a standard nebulizer, with first U.S. patient dosing targeted for late 2026.
Aspen Neuroscience Publishes Preclinical Data on Parkinson’s iPSC-Derived Cell Therapy
Researchers used whole-genome sequencing and a machine-learning RNA assay to assess dopamine neuron precursors made from patients’ skin cells for identity and consistency.
Celularity to Manufacture MuseCell Innovations Therapies in the US
The initial program will use qualified perinatal starting materials and the licensed Dezawa Method, with product-specific testing and release criteria.
Novadip Secures €10.4M for Pivotal Phase 3 Bone Repair Cell Therapy Trial
The ongoing US and EU study is testing NVD003, an autologous cell-based therapy, in patients with a rare, difficult-to-treat pediatric bone condition.